4D Pharma PLC - Leeds-based pharmaceuticals - Says part A of its phase I/II trial for MRx-4DP0004 achieved the primary endpoints of safety and tolerability of the drug. Multiple secondary endpoints of the study also showed positive trends in improving asthma control, which supports the progression into Part b of the Phase I/II trial. MRx-4DP0004 is an orally-delivered single strain live biotherapeutic being developed for the treatment of asthma.
"The further clinical results announced today are highly encouraging. Beyond achieving the primary endpoint, we have seen positive trends in multiple secondary endpoints of efficacy that we will be assessing in Part B," Chief Executive Duncan Peyton comments.
Current stock price: 40.20 pence, up 5.5%
12-month change: down 65%
By Abby Amoakuh; abbyamoakuh@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
